About Hospira (NYSE:HSP)
Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Industry, Sector and Symbol
Industry Generic Pharmaceuticals
Trailing P/E Ratio37.6401673640167
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity16.51%
Return on Assets8.65%
Hospira (NYSE:HSP) Frequently Asked Questions
What is Hospira's stock symbol?
Hospira trades on the New York Stock Exchange (NYSE) under the ticker symbol "HSP."
How were Hospira's earnings last quarter?
Hospira, Inc. (NYSE:HSP) issued its quarterly earnings results on Wednesday, July, 29th. The healthcare company reported $0.85 EPS for the quarter, topping analysts' consensus estimates of $0.78 by $0.07. The healthcare company earned $1.20 billion during the quarter, compared to analysts' expectations of $1.18 billion. Hospira had a return on equity of 16.51% and a net margin of 12.15%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.72 earnings per share. View Hospira's Earnings History.
Who are some of Hospira's key competitors?
Some companies that are related to Hospira include Nokia (NOK), Fresenius Medical Care AG & Co. (FMS), Moody's (MCO), BT Group (BT), Nutrien (NTR), ServiceNow (NOW), DXC Technology (DXC), Pioneer Natural Resources (PXD), Deutsche Bank (DB), Chunghwa Telecom (CHT), McKesson (MCK), Roper Technologies (ROP), Edwards Lifesciences (EW), VF (VFC), Hewlett Packard Enterprise (HPE), Sempra Energy (SRE), CRH (CRH) and ICICI Bank (IBN).
Has Hospira been receiving favorable news coverage?
Media headlines about HSP stock have trended somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hospira earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the healthcare company an impact score of 45.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Hospira?
Shares of HSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hospira's stock price today?
One share of HSP stock can currently be purchased for approximately $89.96.
How big of a company is Hospira?
Hospira has a market capitalization of $15.56 billion.
How can I contact Hospira?
Hospira's mailing address is 275 N Field Dr, LAKE FOREST, IL 60045-2579, United States. The healthcare company can be reached via phone at +1-847-9376472.
MarketBeat Community Rating for Hospira (HSP)MarketBeat's community ratings are surveys of what our community members think about Hospira and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hospira (NYSE:HSP) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Hospira (NYSE:HSP) Earnings History and Estimates Chart
Hospira (NYSE HSP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/29/2015||Q215||$0.78||$0.85||$1.18 billion||$1.20 billion||View||N/A|
|4/28/2015||Q115||$0.51||$0.97||$1.08 billion||$1.18 billion||View||N/A|
|2/12/2015||Q414||$0.41||$0.53||$1.12 billion||$1.13 billion||View||Listen|
|11/6/2014||Q314||$0.53||$0.74||$1.08 million||$1.15 billion||View||Listen|
|7/30/2014||Q214||$0.56||$0.72||$1.05 billion||$1.14 billion||View||Listen|
|4/30/2014||Q114||$0.49||$0.60||$1.02 billion||$1.10 billion||View||Listen|
|2/12/2014||Q413||$0.50||$0.51||$1.06 billion||$1.10 billion||View||Listen|
|11/6/2013||Q3 2013||$0.45||$0.51||$993.94 million||$1.01 billion||View||N/A|
|7/31/2013||Q2 2013||$0.51||$0.55||$1.03 billion||$1.03 billion||View||Listen|
|5/1/2013||Q1 2013||$0.44||$0.52||$979.33 million||$884.00 million||View||Listen|
|2/13/2013||Q4 2012||$0.54||$0.55||$1.04 billion||$1.10 billion||View||Listen|
|11/7/2012||Q312||$0.45||$0.47||$987.67 million||$994.00 million||View||N/A|
Hospira (NYSE:HSP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Hospira (NYSE:HSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Hospira (NYSE HSP) Insider Trading and Institutional Ownership History
Hospira (NYSE HSP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/2/2015||Matthew R Stober||SVP||Sell||21,833||$87.49||$1,910,169.17|| |
|2/27/2015||Matthew R Stober||SVP||Sell||25,338||$87.47||$2,216,314.86|| |
|2/17/2015||Thomas E Werner||CFO||Sell||1,566||$87.35||$136,790.10|| |
|1/15/2015||Thomas E Werner||CFO||Sell||10,000||$61.56||$615,600.00|| |
|1/12/2015||Matthew R Stober||SVP||Sell||2,000||$61.80||$123,600.00|| |
|12/15/2014||Thomas E Werner||CFO||Sell||10,000||$60.86||$608,600.00|| |
|12/2/2014||Richard J Hoffman||CAO||Sell||21,850||$60.32||$1,317,992.00|| |
|11/25/2014||Marc J Yoskowitz||SVP||Sell||11,523||$59.93||$690,573.39|| |
|11/24/2014||Kenneth F Meyers||SVP||Sell||46,250||$59.66||$2,759,275.00|| |
|11/17/2014||Thomas E Werner||CFO||Sell||10,000||$57.73||$577,300.00|| |
|9/15/2014||Thomas E Werner||CFO||Sell||10,000||$52.74||$527,400.00|| |
|8/15/2014||Thomas E Werner||CFO||Sell||10,000||$55.13||$551,300.00|| |
|7/15/2014||Thomas E Werner||CFO||Sell||10,000||$51.50||$515,000.00|| |
|6/16/2014||Thomas E Werner||CFO||Sell||10,000||$50.82||$508,200.00|| |
|5/21/2014||Thomas Werner||CFO||Sell||30,000||$47.98||$1,439,400.00||54,614|| |
|5/16/2014||Connie Curran||Director||Sell||2,000||$47.44||$94,880.00||46,390|| |
|5/14/2014||Barbara Bowles||Director||Sell||2,000||$47.77||$95,540.00||26,219|| |
|5/13/2014||Richard Hoffman||CAO||Sell||15,000||$48.07||$721,050.00||29,440|| |
|5/12/2014||Brian Smith||SVP||Sell||40,000||$48.00||$1,920,000.00||52,635|| |
|3/14/2014||Matthew Stober||SVP||Sell||19,217||$42.28||$812,494.76||57,363|| |
|2/26/2014||Thomas Werner||CFO||Sell||20,000||$42.53||$850,600.00||42,785|| |
|9/11/2013||Richard J Hoffman||CAO||Sell||9,850||$39.38||$387,893.00|| |
|8/16/2013||Matthew Stober||SVP||Sell||4,990||$40.12||$200,198.80||48,619|| |
|6/7/2013||Sumant Ramachandra||SVP||Sell||23,702||$35.69||$845,924.38|| |
Hospira (NYSE HSP) News Headlines
Hospira (NYSE:HSP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hospira (NYSE:HSP) Income Statement, Balance Sheet and Cash Flow Statement
Hospira (NYSE HSP) Stock Chart for Saturday, March, 24, 2018